Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14629808 | 0.90 | F10 (0.46) | F10KCNH2KLKB1 | |
| SCHEMBL10179737 | 0.88 | NPC1 (0.51) | F10KCNH2NPC1PKMRAB9A | |
| SCHEMBL12133048 | 0.87 | F10 (0.62) | F10KCNH2 | |
| SCHEMBL14404271 | 0.86 | F10 (0.49) | F10KCNH2NPC1RAB9A | |
| SCHEMBL14404489 | 0.85 | F10 (0.52) | F10KCNH2KLKB1 | |
| SCHEMBL14404620 | 0.78 | F10 (0.56) | F10KCNH2KLKB1NPC1PKM | |
| SCHEMBL10181011 | 0.78 | NPC1 (0.52) | F10KCNH2NPC1PKMRAB9A | |
| SCHEMBL14629909 | 0.77 | F10 (0.70) | F10KCNH2 | |
| SCHEMBL12134527 | 0.77 | F10 (0.62) | F10KCNH2NPC1PKMRAB9A | |
| SCHEMBL14404272 | 0.77 | F10 (0.58) | F10KCNH2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | F10 18/4885KCNH2 1101/4885KLKB1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.